What elements should be included in the Phase IV study design?

• A. Primary and secondary endpoints and plans for analysis
• B. Patient recruitment only
• C. Only adverse event monitoring
• D. Preclinical studies

Answer: (C)

In Phase IV, the study design should specify what will be measured and how those measures will be analyzed. This phase focuses on long-term safety and real-world effectiveness after a product is marketed, so clearly defined primary and secondary endpoints and a planned analysis approach are essential. They guide what data to collect, how to interpret results, and how to handle statistical issues like sample size and missing data.

While monitoring adverse events is a key part of post-market surveillance, restricting the design to adverse events alone misses important information about how the product performs in broader use, including efficacy signals and other outcomes, and it provides no plan for analyzing the collected data. Preclinical studies are not part of Phase IV; those occur before human trials to assess safety and biology.

So the best approach is to include defined primary and secondary endpoints and a clear plan for analysis to evaluate safety and effectiveness in the real-world setting.